---
title: 'ACMG Clinically Relevant Mutations for Cancer'
date: 2022-10-01
permalink: /posts/2022/09/blog-post-18/
tags:
  - Penn Medicine Biobank
  - Cancer risk
  - GWAS
  - Polygenic risk score
  - PRS
---

The majority of this post is taken from the following paper, written by (Miller et al., 2022)[https://www.gimjournal.org/article/S1098-3600(22)00723-7/fulltext#tbl1]

List of clinically relevant mutations for cancer. The majority of the below are autosomal dominant and all pathogenic and likely pathogenic variants should be evaluated.
  1. APC - FAP
  2. RET - Thyroid cancer, MEN type 2
  3. BRCA1 - breast cancer
  4. BRCA2 - breast cancer
  5. PALB2 - breast cancer
  6. SDHD - Hereditary paraganglioma-pheochromocytoma syndrome
  7. SDHAF2 - "
  8. SDHC- "
  9. SDHB- "
  10. MAX- "
  11. TMEM127 - "
  12. BMPR1A - Juvenile polyposis syndrome
  13. SMAD4 - Juvenile polyposis syndrome
  14. TP53- Li Fraumeni
  15. MLH1 - Lynch syndrome (HNPCC)
  16. MSH2 - Lynch syndrome (HNPCC)
  17. MSH6 - Lynch syndrome (HNPCC)
  18. PMS2 - Lynch syndrome (HNPCC)
  19. MEN1 - Multiple endocrine neoplasia type 1
  20. MUTYH - MUTYH (MYH)-associated polyposis
  21. NF2 - Neurofibromatosis type 2
  22. STK11 - Peutz-Jeghers syndrome 
  23. PTEN - PTEN hamartoma tumor syndrome
  24. RB1 - Retinoblastoma
  25. TSC1 - Tuberous sclerosis complex
  26. TSC2 - Tuberous sclerosis complex
  27. VHL - von Hippel-Lindau syndrome
  28. WT1 - Wilm Tumor
  
It sounds like Dr. Maxwell is interested in investigating all of the above, including several more genes: BRIP1, RAD51C, RAD51D, HOXB13, ATM and CHEK2.
